Healthcare Industry News: Sjogren's syndrome
News Release - January 19, 2006
PDI and Align Pharmaceuticals Sign Multi-Year Commercialization AgreementPDI Sales Team to represent three new oncology drugs
SADDLE RIVER, N.J., Jan. 19 (HSMN NewsFeed) -- PDI, Inc. (Nasdaq: PDII ), a diversified sales and marketing services provider to the biopharmaceutical industry, today announced that it has entered a three-year agreement with Align Pharmaceuticals to assist them with the commercialization of their new product entries for the oncology market.
PDI will initially provide a sales team of 40 field representatives to oversee the sales of three oncology products recently acquired by Align. Two of the drugs, Numoisyn Lozenges and Numoisyn Liquid were designed for xerostomia, dry mouth caused by radiation therapy or Sjogren's syndrome. Xclair the third product approved to treat the symptoms of radiation dermatitis. The primary audience will be radiation oncologists, with additional calls made to select rheumatologists.
As an emerging biopharmaceutical company, Align Pharmaceuticals was founded to market recently approved biopharmaceuticals. Their intent is to form strategic alliances with key partners to pursue their mission, rather than develop its own internal infrastructure. PDI was chosen to be a key partner as Align embarks on its initial commercialization effort.
As part of the agreement, PDI will utilize their state-of-the-art Communicator(TM) technology, an interactive web-based tool sales representatives use to reinforce key messages and address questions for their targeted physicians. This proprietary e-communications platform deepens the relationship between the representative and physician by providing additional resources to physicians and their staffs, while increasing the frequency of interactions.
Larry Ellberger, PDI's Interim CEO, said, "PDI has a great track record of providing outstanding sales teams and other services to large and mid-tier pharmaceutical companies. We are also strategically committed to continuing to develop sales and marketing partnerships with emerging companies, whether U.S. or internationally based, that are developing or licensing in drugs."
Steve Budd, President of PDI, Inc. added, "We have a long history of developing high performance specialty teams with all the requisite infrastructure to support the commercialization process, whether for established or emerging pharmaceutical companies. We are delighted that this engagement allows us to once again show our strength in the specialty marketplace particularly in the oncology market where we have a strong track record of success."
Bill Collins, CEO of Align said, "We were looking for a strategic partner to help us build a company that can win in the marketplace without building our own infrastructure. PDI's history of building effective specialty teams, coupled with their capabilities in medical education and marketing research, precisely matched our needs in launching our commercialization effort." Mr. Collins stated that, "Align is excited about providing physicians the opportunity to provide new options for improving their patient's quality of life by utilizing Xclair, Numoisyn Liquid or Lozenges."
PDI, Inc. (Nasdaq: PDII ) is a diversified sales and marketing services provider to the biopharmaceutical industry. PDI's comprehensive set of outsourced sales teams and marketing solutions is designed to increase its clients' strategic flexibility and enhance their efficiency and profitability. Headquartered in Saddle River, NJ, PDI also has offices in Pennsylvania and Illinois.
PDI's sales and marketing services include dedicated contract sales, Select Access(TM), our targeted sales solution that leverages an existing sales team, marketing research and consulting; and medical education and communications. The company's experience extends across multiple therapeutic categories and includes office and hospital-based initiatives.
PDI's commitment is to deliver innovative solutions, unparalleled execution and superior results for its clients. PDI maintains some of the longest standing sales and marketing relationships in the industry. Recognized as an industry pioneer, PDI remains committed to continued innovation and results.
For more information, visit the Company's website at http://www.pdi-inc.com.
This press release contains forward-looking statements regarding future events and financial performance. These statements involve a number of risks and uncertainties and are based on numerous assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond PDI's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, changes in our operating expenses, adverse patent rulings, FDA, legal or accounting developments, competitive pressures, failure to meet performance benchmarks in significant contracts, changes in customer and market requirements and standards, the impact of any stock repurchase programs, and the risk factors detailed from time to time in PDI's periodic filings with the Securities and Exchange Commission, including without limitation, PDI's Annual Report on Form 10-K for the year ended December 31, 2004, and PDI's periodic reports on Form 8-K filed with the Securities and Exchange Commission since January 1, 2005. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. PDI undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.